(NASDAQ: VNDA) Vanda Pharmaceuticals's forecast annual revenue growth rate of 23.07% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 89.75%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.9%.
Vanda Pharmaceuticals's revenue in 2025 is $203,467,000.On average, 1 Wall Street analysts forecast VNDA's revenue for 2025 to be $13,391,369,532, with the lowest VNDA revenue forecast at $13,391,369,532, and the highest VNDA revenue forecast at $13,391,369,532. On average, 1 Wall Street analysts forecast VNDA's revenue for 2026 to be $18,908,521,600, with the lowest VNDA revenue forecast at $18,908,521,600, and the highest VNDA revenue forecast at $18,908,521,600.
In 2027, VNDA is forecast to generate $22,010,700,925 in revenue, with the lowest revenue forecast at $22,010,700,925 and the highest revenue forecast at $22,010,700,925.